Addex Therapeutics Ltd (ADXN)
SIX
Closed
Oct 7, 2026
Day's Range
0.022252 wk Range
0.0180Overview - ADXN - Addex Therapeutics Ltd
Key Statistics
Valuation
Enterprise Value
2.10M
P/E (Trailing)
‪-0.40‬
P/E (Forward)
‪-0.61‬
PEG Ratio
‪-0.61‬
Price / Sales (TTM)
‪34.12‬
Price / Book
‪0.87‬
EV / EBITDA
‪-0.78‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-6,238.81%‬
Return on Assets
‪-23.59%‬
Return on Equity
‪-122.28%‬
Ownership
Shares Outstanding
119.31M
Float
97.06M
Held by Insiders
‪9.99%‬
Held by Institutions
‪1.04%‬
Price stats
Beta
‪1.96‬
50-Day Avg
‪0.0332‬
200-Day Avg
‪0.0439‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
1 analysts
Market Cap - ADXN - Addex Therapeutics Ltd
Peers - ADXN - Addex Therapeutics Ltd
Peer Comparison
Compared with companies in Biotechnology listed on SIX.
- ADXNSIXAddex Therapeutics Ltd3.73MMarket Cap-145.53%52-week change-0.41P/E (Trailing)‪0.00%‬Profit Margin
- BIONSIXBB Biotech AG3.08BMarket Cap+42.23%52-week change2.29P/E (Trailing)‪127.31%‬Profit Margin
- BSLNSIXBasilea Pharmaceutica Ltd851.32MMarket Cap+32.82%52-week change17.13P/E (Trailing)‪21.17%‬Profit Margin
- BIOVSIXBioVersys AG153.39MMarket Cap-8.78%52-week change-6.84P/E (Trailing)‪-386.62%‬Profit Margin
Profile Summary - ADXN - Addex Therapeutics Ltd
About
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company headquartered in Geneva, Switzerland, specializing in the development of novel small molecule allosteric modulators for neurological disorders. These orally available drugs target receptors to offer potential therapeutic advantages over conventional…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
